Voting after Friday’s conference, the Supreme Court followed the Solicitor General’s advice and denied certiorari in Hikma Pharmaceuticals USA Inc. v. Vanda Pharmaceuticals Inc. (No. 18-817), but also denied cert. in Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC (No. 19-430), and HP Inc. v. Berkheimer (No. 18-415).
Perhaps the Court has decided its work with 35 USC § 101 is done, and the rest is up to Congress.
Autor(es)
Informações relacionadas
December 9, 2025
Health Care Law Today
How Following “Doctors’ Orders” Provided a Defense in a First Circuit FCA Case
When it comes to False Claims Act (FCA) litigation, clinical laboratories often find themselves in the crosshairs. But the First…
December 9, 2025
Foley Viewpoints
White House Orders Task Forces To Investigate Food Industry
Last month, we reported on the Department of Justice (“DOJ”) ramping up antitrust enforcement in the agriculture industry, including…
December 8, 2025
Foley Viewpoints
2026 Outlook: AI, IPOs, and the New “Normal” in Venture & Private Equity
Key Takeaways The 2026 outlook for market activity is cautiously optimistic amid ongoing challenges.Private equity firms are shifting to…